Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated Jun 10, 2025, titled "Press Release on US-FDA Compliance status for OneSource".
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
OneSource Specialty Pharma's flagship drug-device combination facility in Bangalore has received a 'Voluntary Action Indicated' (VAI) classification from the USFDA, confirming its continued compliance. The USFDA had inspected the facility from March 20 to March 28, 2025, and issued a Form 483 with four observations. After the company submitted a comprehensive response, the agency classified the outcome as VAI, officially closing the inspection. This facility is central to the company's manufacturing of drug-device combinations, biologics drug substances, and complex injectables, and is expected to support partner launches of key GLP-1 products in late FY26.
This is a positive outcome for shareholders, as the VAI classification means no mandatory corrective action is required from the USFDA, removing a regulatory overhang. It strengthens OneSource's credibility as a compliant CDMO partner and supports upcoming commercial launches, which could positively influence the stock price.